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ABSTRACT
Background: Despite the fact that bronchioles are involved in asthma, there have been limited asthmatic
cases showing marked centrilobular opacities on computed tomography (CT) chest scans. Systemic corti-
costeroids have been administered in such cases, but the efficacy of extra-fine particle inhaled corticosteroids
has not been assessed.
Case Summary: A previously healthy 64-year-old man presented with a four-month history of productive
cough and progressive dyspnea despite a combination therapy with inhaled salmeterol (50 μg bid) and flutica-
sone (500 μg bid), sustained-release theophylline, and pranlukast because of suspicion of asthma. Physical ex-
amination revealed wheezing at the end of forced expiration. High resolution CT chest scan showed diffuse
centrilobular opacities, bronchiectatic changes, and bronchial wall thickening. Transbronchial lung biopsy,
bronchoalveolar lavage fluid, and transbronchial biopsy all showed predominant eosinophil infiltrates, suggest-
ing that eosinophilic inflammation across the entire airway tree caused the abnormal CT findings. Alveolar frac-
tion of exhaled nitric oxide level, a non-invasive marker of eosinophilic peripheral airway inflammation, was also
elevated. Because he refused systemic corticosteroids, inhaled ciclesonide (400 μg bid) and inhaled tiotropium
were added on to his current medication under careful observation. His symptoms, pulmonary function and CT
findings promptly improved, and he had fully recovered at follow-up.
Discussion: Extra-fine particle inhaled corticosteroids could be an alternative approach in centrilobular opaci-
ties caused by eosinophilic peripheral airway inflammation.
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INTRODUCTION
In 2001, Takayanagi et al. have proposed a new dis-
ease entity of eosinophilic bronchiolitis that shows
centrilobular opacities on computed tomography
(CT) scans,1 which was followed by several similar
reports of eosinophilic bronchiolitis with or without
asthma.2 Accumulation of such cases may provide
deeper understanding of links between peripheral air-
way dysfunction and eosinophilic inflammation. In
the previous cases, however, details of peripheral air-
way function and its responses to treatment have
been poorly described. In addition, the efficacy of
extra-fine particle inhaled corticosteroids that may al-
low better access to the peripheral airways has not
been assessed. We here report that the addition of an
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Table　1　Pulmonary function results and markers of eosinophilic infl ammation before and after intensifying treatment
Before 
intensifi cation†
2 wk after 
intensifi cation 2 mo after 4 mo after 1 yr after
VC, L (%pred) 2.43 (72.8) 2.97 (88.9) 3.74 (112.0) 3.99 (119.5) 4.22 (126.3)
FEV1, L (% pred) 0.88 (35.2) 1.34 (53.6) 2.52 (100.4) 3.03 (120.7) 3.23 (129.2)
PEF, L/min 250 470 550 550 600
RV/TLC, % 41.0 - 26.6 28.1 30.2
ΔN2, % 10.1 3.6 3.4 1.7 0.5
Blood eosinophils, % 13.1 23.0 13.0 9.0 6.8
FeNO50, ppb 15.0 37.1 38.0 40.6 31.1
CANO,TMAD, ppb 9.3 5.0 5.0 1.1 1.0
† Treatment intensifi cation = Addition of inhaled ciclesonide and tiotropium.
VC, vital capacity; FEV1, forced expiratory volume in one second; PEF, peak expiratory fl ow; RV/TLC, residual volume/total lung capacity; 
ΔN2, slope of alveolar plateau of the single-breath nitrogen washout curve; FeNO50, Fraction of exhaled nitric oxide (NO) at 50 ml/s; 
CANO,TMAD,  Alveolar fraction of exhaled NO adjusted for trumpet shape airways and axial diffusion.
extra-fine particle inhaled corticosteroid and an in-
haled tiotropium was effective for treating asthma
with marked centrilobular opacities on a CT scan, by
showing responses of peripheral airway function and
alveolar fraction of exhaled nitric oxide (NO) levels, a
non-invasive marker of eosinophilic peripheral airway
inflammation, to the treatment.
CLINICAL SUMMARY
A previously healthy 64-year-old man presented with
a four-month history of productive cough and pro-
gressive dyspnea despite a combination therapy with
inhaled salmeterol (50 μg) and fluticasone (500 μg
bid), sustained-release theophylline, and pranlukast
because of suspicion of asthma. These medications
did not sufficiently improve his symptoms. He had a
smoking history of 20 pack-years, but had quit smok-
ing more than 20 years before. He had experienced
allergic rhinitis symptoms during Japanese cedar pol-
len season for 8 years. Physical examination revealed
wheezing at the end of forced expiration. Blood tests
showed eosinophilia (13.1%), elevated IgE (630 IU
ml), and mild hypoxemia while breathing room air
(PaO2 = 66.5 mmHg). He was sensitized to multiple
inhaled allergens. Other serological tests showed no
remarkable findings. Pulmonary function tests re-
vealed severe airflow limitation (pre- and post- bron-
chodilator FEV1 of 0.88 L and 0.89 L, respectively), in-
creased residual volume and increased slope of the
alveolar plateau during single-breath nitrogen wash-
out test (ΔN2) (Table 1). The alternative indices of
small airway caliber and reactance measured using
the impulse oscillometry system (MasterScreenTM;
Erich Jaeger, Hoechberg, Germany) were also im-
paired; The frequency dependence of respiratory re-
sistance (Rrs) between 5 and 20 Hz, i.e., Rrs5-Rrs20,
was 0.25 kPa・L-1・s; the reactance at 5 Hz, i.e., Xrs
5, was -0.34 kPa・L-1・s; and the reactance area, i.e.,
the integral of Xrs from 5 Hz to the resonant fre-
quency AX was 3.39 kPa・L-1. On admission meth-
acholine challenge test was not performed because of
the severe airflow limitation. Sputum showed pre-
dominant eosinophils and yielded no growth of mi-
croorganisms, including fungi andMycobacteria.
High resolution CT chest scan showed diffuse cen-
trilobular or tree-in-bud opacities, bronchiectatic
changes, and bronchial wall thickening, but no air-
space consolidation or emphysematous changes (Fig.
1a-c). Sinusitis was not observed on a CT scan of the
sinuses. The exhaled NO level was measured at three
flow rates, 50 mls, 100 mls, and 200 mls, using a
chemiluminescence analyzer (NOA280, Sievers, CO,
USA), and alveolar fraction of exhaled NO level was
determined by a trumpet model with axial diffusion
(CANO,TMAD).3,4 CANO,TMAD level was numerically
higher than median (3.9 ppb) or average (5.5 ppb) of
the measured values of 70 patients with stable asthma
in our institution.4 The elevation of CANO,TMAD
strongly suggested the presence of eosinophilic in-
flammation in the peripheral airways.
Transbronchial lung biopsy (TBLB) revealed
eosinophilic infiltration into alveolar septa (Fig. 2a),
and eosinophils (60%) were predominant in bron-
choalveolar lavage fluid (BALF). Transbronchial bi-
opsy obtained at the bifurcation of anterior basal seg-
mental bronchus and lateral basal segmental bron-
chus of the right lung also showed eosinophil infil-
trates, basement membrane thickening, and an in-
creased area of airway smooth muscle (Fig. 2b).
Based on these clinico-pathophysiological findings,
we speculated that eosinophilic inflammation associ-
ated with asthma might have involved the bronchi-
oles, which could explain the centrilobular opacities
on a CT scan. Because he refused systemic corti-
costeroids use, inhaled ciclesonide (400 μg bid), an
extra-fine particle inhaled corticosteroid, and inhaled
tiotropium were added on to his current medication
under careful observation. Within 2 weeks, the pa-
tient’s symptoms and pulmonary function promptly
improved. One year later, he had fully recovered (Ta-
Centrilobular Nodules in Asthmatic Lung
Allergology International Vol 60, No3, 2011 www.jsaweb.jp 383
Fig.　1　Computed tomography chest scans on admission (a, b, c) and at 
2 months after intensifying the treatment (d).
ble 1 and Fig. 1d), showing improvement of airway
impedance; an Rrs5-Rrs20 of 0.03 kPa・L-1・s, Xrs5
of -0.13 kPa・L-1・s, and AX of 0.37 kPa・L-1. On sub-
sequent evaluation, he showed airway hyperrespon-
siveness to inhaled methacholine (AstographTM;
Chest, Tokyo, Japan; Dmin, 10.4 Units).
DISCUSSION
Despite the fact that the bronchioles are involved in
asthma,5 there have been a limited number of cases
with asthma or eosinophilic lung disease that showed
marked centrilobular opacities on chest CT scans, ex-
cept for recent reports of eosinophilic bronchiolitis
with or without asthma.1,2 Here we presented an asth-
matic case showing diffuse centrilobular or tree-in-
bud opacities on a CT scan that was successfully
treated with an extra-fine particle inhaled corticoster-
oid and an inhaled tiotropium. Although a definitive
lesion involving bronchioles was not obtained in this
case due to technical issues with the transbronchial
approach, the presence of eosinophilic bronchiolitis
was highly suspected as eosinophil infiltrates were
observed across the entire airway tree (i.e., in TBLB,
BALF and bronchial biopsy samples).
To the best of our knowledge, this is the first re-
port showing that the addition of an extra-fine particle
inhaled corticosteroid, as well as inhaled tiotropium,
was effective for treating asthma with marked centri-
lobular opacities on a CT scan. We carefully observed
the patient’s condition to avoid under-treatment, be-
cause previous cases with eosinophilic bronchiolitis
with or without asthma1,2 consistently used medium
to high doses of systemic corticosteroids. Previously
we have also found that inhaled chlorofluorocarbon-
beclomethasone dipropionate alone failed to treat
chronic eosinophilic pneumonia.6 Despite these con-
cerns, our patient promptly responded to medications
without the administration of systemic corticosteroids
and did not deteriorate thereafter. The addition of in-
haled ciclesonide to the medication may have exerted
anti-inflammatory effects, possibly because its particle
size was adequately small for it to reach the periph-
eral airways, but also because of its delivery system.
This patient might have had reduced inspiratory flow
rates, in which case the use of the aerosol formula-
tion, such as of ciclesonide, may be advantageous
over the dry powder formulation. In addition, the in-
crease in the total amount of inhaled corticosteroids
may have suppressed the remaining inflammation
throughout the airways. The additive effects of in-
haled tiotropium should also be acknowledged, since
cholinergic tone increases particularly in asthmatics
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Fig.　2　Transbronchial lung biopsy (a) and transbronchial 
biopsy (b). Arrow heads indicate eosinophil infi ltrates.
a
b
with moderate to severe disease.7 Further studies are
necessary, since we did not use any placebo control
in this case; nonetheless, from the results obtained
we can conclude that extra-fine particle inhaled corti-
costeroids may be an alternative approach for treat-
ing eosinophilic peripheral airway inflammation.8,9
Unlike previous reports of eosinophilic bronchioli-
tis,1,2 we have clearly shown physiological abnormali-
ties in the peripheral airways and their responses to
treatment. Peripheral airway obstruction and ventila-
tion heterogeneity at baseline as expressed in ele-
vated RVTLC and ΔN2 were improved in parallel
with the improvement of symptoms and CT findings
after intensifying the treatment. Moreover we
showed improvement of alveolar NO level, a non-
invasive marker of eosinophilic peripheral airway in-
flammation, after intensifying the treatment. Alveolar
NO level determined by a two compartment model
(CANO)10 has been used as a non-invasive tool to as-
sess eosinophilic inflammation of peripheral airway
alveolar regions. Recently corrected models of CANO,
i.e., CANO,TMAD that incorporated trumpet shaped air-
ways and axial diffusion have been developed to cor-
rect the effect of axial contamination by small airway
NO diffusion on CANO.3,11 Changes in CANO,TMAD lev-
els in our case may suggest the usefulness of multiple
expiratory flow measurements of NO to determine al-
veolar NO levels particularly when eosinophilic pe-
ripheral airway inflammation is suspected.
NO level at an expiratory flow of 50 mls (FeNO50)
before intensifying the treatment was unexpectedly
low (Table 1). The low FeNO50 level can be ex-
plained by an elegant simulation model that shows
that increased ventilation heterogeneity and predomi-
nant NO production in the peripheral airways de-
creases FeNO50 levels when compared to levels un-
der uniform ventilation and NO production.12 Indeed,
the FeNO50 level paradoxically increased when venti-
lation heterogeneity was partially resolved.
It was important to determine whether or not this
patient had asthma. On admission to the hospital, 200
μg of inhaled salbutamol was administered, but it did
not change his FEV1 level. We believe that the reason
for this was the dose of salbutamol administered,
which was insufficient to be delivered throughout the
airways, since his airways were severely obstructed
because of inflammation accompanied by airway
edema and mucus plugging. After bronchoscopic ex-
amination, when the wheezing and dyspnea wors-
ened, 300 μg salbutamol followed by 50 μg nebulized
procaterol was administered, and the patient’s condi-
tion improved. This may suggest that the airway ob-
struction in this patient was reversible with bron-
chodilators. Furthermore, airway hyperresponsive-
ness to inhaled methacholine, eosinophilic inflamma-
tion in the central airway, and partial improvement of
symptoms by asthma medication, including
sustained-release theophylline and pranlukast, sug-
gest that this patient had asthma.
In conclusion, we have comprehensively reported a
rare case of asthma that presented with centrilobular
opacities on a CT scan. The presence of eosinophilic
peripheral airway inflammation was suspected due to
an elevated alveolar NO level, which was confirmed
by the findings of TBLB and BALF. Addition of extra-
fine particle inhaled corticosteroids may attenuate
eosinophilic peripheral airway inflammation.
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